| |
|
| |
| DETAILS |
|
[LIMITED CAPACITY: CONFIRMED GUESTS ONLY]
Summary:
Longevity Investor Network & Lifespan Research Institute (LRI) Translational Research & Venture Showcase (Pitch Event)
Join us for an inside look at Lifespan Research Institute's most advanced translational research programs as they move toward spin-out readiness in 2026. This curated event brings together founders, investors, operators, & scientific leaders at the intersection of aging biology, mitochondrial health, & cellular senescence.
The evening will begin with short, focused talks from LRI's internal translational research teams, highlighting two of our most commercially advanced programs. These efforts exemplify LRI's mission to translate rigorous intramural research into venture-backed companies with the potential for real-world impact.
Following a dedicated networking break, the evening will transition into a curated series of startup pitch sessions spotlighting companies operating at the forefront of longevity, biotechnology, & healthspan innovation. These companies represent a new generation of science-driven ventures translating cutting-edge biology into scalable therapeutic & platform opportunities.
The pitch sessions will feature confirmed companies including LeahLabs, Rethink64, & Repair Biotechnologies, each addressing fundamental drivers of aging & age-related disease through differentiated scientific & engineering approaches. Collectively, these teams are building across critical pillars of the longevity ecosystem-from cellular repair & metabolic resilience to translational strategies designed to move rapidly from discovery into clinical relevance.
These are not speculative concepts, but companies actively shaping how longevity science will be developed, validated, & commercialized over the coming decade. Each pitch will offer insight into the company's scientific thesis, progress to date & long-term vision.
Learn more about LRI's intramural research platform here:
https://www.lifespan.io/our-research/intramural-research/
DETAILS:
Why join? This event offers a unique opportunity to dive into new topics, connect with like-minded individuals, & open doors to exciting possibilities-even the chance to build and/or invest in your next company! You might meet a future portfolio company, collaborator, mentor, or investor, or spark an idea that could lead to the next major startup or scientific breakthrough!
Who Should Join? The select audience will be comprised of Investors, Family Offices, Corporate Biotech Venture Partners with select researchers & startups operating in the longevity biotech field.
SCHEDULE:
Sunday January 11th, 2026
1:45PM: Check-In & Networking
2:30PM-2:50PM: Boominathan Lab Presentation (Restoring Mitophagy Surveillance)
2:50PM-3:10PM: Sharma Lab Presentation (A Universal Surface Marker of Senescence)
3:10PM-3:40PM: Networking
3:40PM-4:00PM: Leah Labs Presentation
4:00PM-4:20PM: Rethink64 Presentation
4:20PM-4:40PM: Repair Biotechnologies
4:40PM-5:00PM: Presentation 6 (Coming Soon!)
5:00PM-6:00PM: Networking
Presenting Team & Companies:
Restoring Mitophagy Surveillance to Re-Establish Mitochondrial Health - Boominathan Lab
This program focuses on restoring the body's innate ability to regulate mitochondrial quality control. A mutation-agnostic lead compound has been identified that enhances the clearance of damaged mitochondria, enabling durable remodeling of the mitochondrial network & restoration of healthy mitochondrial balance. This work represents a highly differentiated approach to mitochondrial dysfunction with broad therapeutic potential.
Lab overview:
https://www.lifespan.io/our-research/boominathan-lab/
LAMP1: A Universal Surface Marker of Senescence - Sharma Lab
This program has identified cell-surface LAMP1 as a robust, senescence-specific biomarker across human & mouse tissues. LAMP1 expression strongly correlates with canonical senescence markers & is elevated in fibrotic lung tissue. The team has developed LAMP1-targeting antibody-drug conjugates (ADCs) to selectively eliminate senescent cells, creating a new modality for senolytic intervention.
Lab overview:
https://www.lifespan.io/our-research/sharma-lab/
Leah Labs
Chimeric Antigen Receptor (CAR) T cell therapies induce lasting remissions in hematologic malignancies, but their extension to solid tumors is constrained by the biology of legacy therapeutic designs. LEAH Labs uses generative protein engineering to uplift CAR components & T cell biology to augment signaling strength, increase persistence, & impart functional longevity. We've built a suite of de novo molecules to augment CAR-T cells including new-to-nature transmembrane domains & peptide transcription factor inhibitors that increase CAR-T cell fitness. Uniquely, we use natural cancer in dogs as a fast, capital-efficient & translational model, & we're the first in the world to induce remissions in pet dogs with cancer using CAR-T cells. We're building for near-term commercialization & early revenue under USDA-CVB while creating multiple paths to asymmetric value creation through licensing, co-development, or human company spin-outs from our novel assets. At LEAH Labs, we're building curative cell therapies for pets & their people.
Rethink64
ReThink64's novel Nexus platform enables stable, penetrating & concentrated delivery of next generation drugs like peptides, RNAs & other macromolecules. The company is led by Stanford PhD & second time founder (Turn Bio) Dr. Jay Sarkar. He is backed by a seasoned team of industry professionals out of Stanford Research Institute & Harvard Business School. The Nexus platform has demonstrated high efficiency delivery in both Mice & in Humans with both injection & topical application. ReThink64 is already engaged with their first clients: two in skin aging & a third in dry eye disease, in addition to multiple collaborations with Stanford University.
Repair Biotechnologies
The first-in-class Cholesterol Degrading Platform (CDP). Repair Biotechnologies develops the Cholesterol Degrading Platform, a safe approach to treating medical conditions that arise due to localized accumulations of excess cholesterol. In particular, our treatments can rapidly & dramatically reduce atherosclerotic plaque in arteries, the cause of stroke, heart attack, & other cardiovascular disease.
More Coming Soon!!
INVESTOR ATTENDEES:
Investors From: Coming Soon!
ATTENDANCE:
Where: Valley Research Park
319 N Bernardo Ave, Mountain View, CA 94043, USA
Confirmed Attending Investors From: Longevity Investor Network, Age1, ContinuumHealthVC, DraperVC, LunarVentures, NFX, PioneerFundVC, PearVC, InsightPartners, XPrize, OutsidersFund, Matrix Partners China, HCVC, BackedVC, ARPA-H, E12 Ventures, LongevityTechFund, Longevity Vision Fund, BoxOne Ventures, SOS Ventures, Maximon, Juvenescence, 5AM Ventures, CambrianBio, AltosLabs, Canaan Partners, LongeVC, Methuselah Foundation, CurieBio, Centenarian Fund, Formic Ventures, Khosla Ventures, Prime Movers Lab, Life Science Angels, Emerging Longevity Ventures, HOF Capital, Kaiser Pernamente Ventures, OrbiMed, IndieBio, Apollo Health Ventures, & more!
Lifespan Research Institute (LRI) is a 501(c)(3) nonprofit organization focused on the defeat of age-related disease & the extension of healthy human lifespan - through raising funds & awareness for scientific work addressing the root causes of the aging process, building a thriving ecosystem of mission aligned stakeholders which can be mobilized to strategic action, & spearheading relevant research projects directly. We work to identify, develop, & promote initiatives with outsized impact & the greatest potential to realize widespread access to regenerative medicine solutions targeting the disabilities & diseases of aging.
Lifespan.io Sponsors & Members of the Lifespan Alliance
We are deeply honored by & grateful for the support of our Lifespan Alliance members, whose contributions are integral to our mission to extend healthy human lifespan & overcome age-related disease. These forward-thinking organizations empower our work at the forefront of scientific discovery & advocacy, advancing transformative interventions & fostering breakthroughs that will redefine health & aging for generations to come. Join the Lifespan Alliance today.
The Longevity Investor Network is an initiative of Lifespan Research Institute, a 501(c)(3) nonprofit formed through the merger of SENS Research Foundation & Lifespan.io.
As a 501(c)3 nonprofit, your support is vital to our mission at LRI-consider making a donation to help us continue advancing longevity science & hosting impactful events like this one.
For more information on how to join the Longevity Investor Network, please reach out to javier@lifespan.io
|
|
|
|
|
|
|
|
